Data presented at the SITC further support the use of eftilagimod alpha ("efti") in PD-1 / PD-L1 immune checkpoint inhibitor ("ICI") combinations. These include very encouraging data in normally unresponsive 2nd line HNSCC (head and neck cancer) and 2nd line NSCLC (non-small cell lung cancer) and, as well as further indications of improved responses in the second 1st line NSCLC expansion cohort. The new Phase 2 TACTI-002 interim results show that 5 patients have now seen complete responses to the efti-pembrolizumab combo (2 in 1st line NSCLC and 3 in 2nd line HNSCC), whilst treatment was well tolerated in the total 91 patients. Striking data in normally PD-1 / PD-L1 unresponsive 2nd line HNSCC revealed double the ORR expected from ICI alone, including 3 complete responses. Promising responses were seen in predominantly low PD-L1 expressing 2nd line NSCLC compared to the chemo standard of care triggering entry into the second expansion phase. These increasingly positive data further highlight the potential of efti-ICI combos. With the prospect of a potentially positive read through from BMS's Phase III / registrational trial reporting late 2020E / early 2021E, we reiterate our OUTPERFORM recommendation and AUD$ 0.610 target price.
11 Nov 2020
Striking support for efti - checkpoint inhibitor combos
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Striking support for efti - checkpoint inhibitor combos
Data presented at the SITC further support the use of eftilagimod alpha ("efti") in PD-1 / PD-L1 immune checkpoint inhibitor ("ICI") combinations. These include very encouraging data in normally unresponsive 2nd line HNSCC (head and neck cancer) and 2nd line NSCLC (non-small cell lung cancer) and, as well as further indications of improved responses in the second 1st line NSCLC expansion cohort. The new Phase 2 TACTI-002 interim results show that 5 patients have now seen complete responses to the efti-pembrolizumab combo (2 in 1st line NSCLC and 3 in 2nd line HNSCC), whilst treatment was well tolerated in the total 91 patients. Striking data in normally PD-1 / PD-L1 unresponsive 2nd line HNSCC revealed double the ORR expected from ICI alone, including 3 complete responses. Promising responses were seen in predominantly low PD-L1 expressing 2nd line NSCLC compared to the chemo standard of care triggering entry into the second expansion phase. These increasingly positive data further highlight the potential of efti-ICI combos. With the prospect of a potentially positive read through from BMS's Phase III / registrational trial reporting late 2020E / early 2021E, we reiterate our OUTPERFORM recommendation and AUD$ 0.610 target price.